The development of effective treatments for psychiatric disorders has been proven to be challenging.  Lotus CRO offers a unique level of expertise in the conduct of Central Nervous System (CNS) research..

Early Development Services (Healthy Normal Volunteer)

Early Development Services for early-stage pharma and biotech clients Lotus’ specialty Early Development Services (EDS) group was formed in 2020 to meet the need of our early-stage pharma and biotech clients. Our EDS team members work exclusively in early phase..

Abuse Liability/Potential (HAL/HAP)

Any new drug that has the potential to target sites or permeate the central nervous system requires an assessment of its abuse and dependence liability.  Lotus has historically focused the growth of its services, expertise, and regulatory knowledge in analgesics..


Addiction is a complex disease, often chronic in nature, which affects the functioning of the brain and the body.  Substance use disorder studies require specialized expertise, knowledge, and relationships to get your study up and running as soon as possible.  

Acute Pain

Lotus Clinical Research has developed an acute pain model that offers numerous advantages over traditional models, providing clients with active engagement and recruitment of study subjects, on-site accessibility of surgical and recovery services, and lowered project costs throughout a study’s..

Chronic Pain

From early phase proof of concept through Phase 3 studies, Lotus Clinical Research specializes in designing chronic pain models that address every aspect of chronic pain studies, resulting in greater efficiencies and superior outcomes for sponsors.

Inflammation & Immunology

Coming soon

Renal/Hepatic Impairment

As outlined in their published guidelines, the FDA mandates that pharmaceutical sponsors conduct pharmacokinetic (PK) studies in patients with impaired renal and hepatic function.   With deep experience in executing these trials and our relationship with our ERG network of specialized sites with recruitment expertise..

Metabolic Diseases

Since the first decade of the new millennium, the focus of drug and device development in the metabolic disease space has undergone a significant transition. Emerging opportunities in conditions like diabetes, fatty liver disease, and obesity have begun to displace earlier priorities.